A randomised, open-label, multicentre, Phase III trial of in vivo purging with anti-CD38 (Daratumumab) to enhance myeloma autografting (IPANEMA)

Project Details

Short titleA randomised, open-label, multicentre, Phase III trial of in vivo purging with anti-CD38 (Daratumumab) to enhance myeloma autografting (IPANEMA)
StatusActive
Effective start/end date1/10/2031/03/23

Funding

  • JANSSEN PHARMACEUTICA NV